Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cobolimab

Alternative Names: cobolimab, tsr-022, tsr022, tsr 022
Latest Update: 2025-04-16
Latest Update Note: Clinical Trial Update

Product Description

TIM-3 binding antibody (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03680508)

Mechanisms of Action: TIM3 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cobolimab

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Japan, Korea, Mexico, Netherlands, Poland, Romania, Russia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Phase 2: Cervical Cancer|Hodgkin Lymphoma|Liver Cancer|Melanoma|Uterine Cancer

Phase 1: Colorectal Cancer|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
219451

P2

Recruiting

Melanoma|Hodgkin Lymphoma

2030-11-01

POPSTAR

P2

Recruiting

Melanoma

2029-10-05

NCT06238635

P2

Recruiting

Uterine Cancer|Cervical Cancer

2026-02-01

jRCT2041230056

P3

Not yet recruiting

Non-Small-Cell Lung Cancer

2026-01-31

Recent News Events

Date

Type

Title

02/27/2025

News Article

 Anaptys Announces Participation in March Investor Conferences

02/12/2025

News Article

 Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

02/11/2025

News Article

 Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

02/03/2025

News Article

 Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

11/27/2023

PubMed

 Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.

05/01/2022

PubMed

 New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions